CDKN2A and chronic myelogenous leukemia, BCR-ABL1 positive: Previous data suggested that deletion of antigen receptor genes (IGH, TCR), IKZF1, and/or CDKN2A may support the diagnosis of de novo disease versus blastic phase of CML.[19] Unfortunately, we did not have a line of the related checks.